Impact of Metformin therapy on miR-9, miR-223, and miR-132 and inflammasome-related gen expression in obese and non-obes PCOS patients: A comparative study with healthy controls
The findings suggest that metformin modulates inflammation in PCOS by altering microRNA and inflammasome-related gene expression, thereby reducing inflammatory markers such as IL-1β and miR-9, while enhancing miR-132 and miR-223, which may contribute to improved metabolic and inflammatory profiles. These results support the use of metformin as a BMI-tailored therapeutic strategy for PCOS, warranting further research to confirm its long-term effects and mechanisms.
Authors
- Seyed Reza Mirjalili (ORCID: https://orcid.org/0000-0002-9324-1529)
- Korosh Ashrafi Dehkordi (ORCID: https://orcid.org/0000-0001-7105-731X)
- Fateme Montazeri (ORCID: https://orcid.org/0000-0002-7739-5982)
- Seyed Mehdi Kalantar (ORCID: https://orcid.org/0000-0002-6994-6449)
- Samira Asgharzade (ORCID: https://orcid.org/0000-0003-1334-5625)
- Reyhaneh Azizi (ORCID: https://orcid.org/0000-0002-0996-045X)
- Elham Sadat Hosseini
- Fateme Zare (ORCID: https://orcid.org/0000-0003-0436-9924)
Institutions
- Zanjan University of Medical Sciences (IR)
- Shahrekord University of Medical Sciences (IR)
- Shahid Sadoughi University of Medical Sciences and Health Services (IR)
- Diabetes Research Center
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1371/journal.pone.0335280
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00